Answers are grounded in this paper and cite their sources.
(2019). Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy. Journal of Drug Assessment: Vol. 8, Abstracts from the Seventh Annual National Association of Specialty Pharmacy (NASP) Meeting, pp. 46-47.
No takes yet. Share an insight, caveat, or question.
McCall et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: